{"nctId":"NCT01730040","briefTitle":"Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)","startDateStruct":{"date":"2012-10"},"conditions":["Hypercholesterolemia"],"count":355,"armGroups":[{"label":"Atorvastatin 40 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Atorvastatin","Drug: Placebo"]},{"label":"Ezetimibe 10 mg + Atorvastatin 20 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Atorvastatin","Drug: Ezetimibe","Drug: Placebo"]},{"label":"Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Alirocumab","Drug: Atorvastatin","Drug: Placebo"]},{"label":"Atorvastatin 80 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Atorvastatin","Drug: Placebo"]},{"label":"Rosuvastatin 40 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rosuvastatin","Drug: Placebo"]},{"label":"Ezetimibe 10 mg + Atorvastatin 40 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Atorvastatin","Drug: Ezetimibe","Drug: Placebo"]},{"label":"Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Alirocumab","Drug: Atorvastatin","Drug: Placebo"]}],"interventions":[{"name":"Alirocumab","otherNames":["REGN727/SAR236553"]},{"name":"Atorvastatin","otherNames":[]},{"name":"Ezetimibe","otherNames":["Ezetrol"]},{"name":"Rosuvastatin","otherNames":["Crestor"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients with screening (visit 1) LDL-C greater than or equal to 70 mg/dL with documented CVD, not adequately controlled with a daily dose of atorvastatin. OR\n2. Patients with screening (visit 1) LDL-C greater than or equal to 100 mg/dL at high risk for CVD who are not adequately controlled with a daily dose of atorvastatin.\n\nExclusion Criteria:\n\n1. LDL-C greater than 250 mg/dL\n2. LDL-C less than 70 mg/dL at the screening visit in patients with history of documented CVD\n3. LDL-C less than 100 mg/dL at the screening visit in patients without history of documented CHD or non-CHD CVD, but with other risk factors\n4. TG greater than 400 mg/dL\n5. Homozygous FH (clinically or previous genotyping)\n6. Currently taking a statin that is not atorvastatin\n7. Currently taking Ezetimibe (EZE)\n8. Not on a stable dose of allowable lipid modifying treatments (LMT)\n\n(The inclusion/ exclusion criteria provided above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis","description":"Calculated LDL-C values were obtained from Friedewald formula. Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":"4.6"},{"groupId":"OG001","value":"-20.5","spread":"4.7"},{"groupId":"OG002","value":"-44.1","spread":"4.5"},{"groupId":"OG003","value":"-4.8","spread":"4.2"},{"groupId":"OG004","value":"-21.4","spread":"4.2"},{"groupId":"OG005","value":"-22.6","spread":"4.3"},{"groupId":"OG006","value":"-54","spread":"4.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis","description":"Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \\[whatever atorvastatin, rosuvastatin or ezetimibe\\], whichever came first) (on-treatment analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","spread":"4.6"},{"groupId":"OG001","value":"-23.7","spread":"4.7"},{"groupId":"OG002","value":"-48.6","spread":"4.5"},{"groupId":"OG003","value":"-5.0","spread":"4.4"},{"groupId":"OG004","value":"-22.9","spread":"4.4"},{"groupId":"OG005","value":"-24.5","spread":"4.5"},{"groupId":"OG006","value":"-57.8","spread":"4.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis","description":"Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment (ITT analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.5","spread":"3.9"},{"groupId":"OG001","value":"-22.6","spread":"3.9"},{"groupId":"OG002","value":"-48.4","spread":"3.8"},{"groupId":"OG003","value":"-14.5","spread":"3.2"},{"groupId":"OG004","value":"-23.3","spread":"3.2"},{"groupId":"OG005","value":"-29.7","spread":"3.2"},{"groupId":"OG006","value":"-50.5","spread":"3.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis","description":"Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \\[whatever atorvastatin, rosuvastatin or ezetimibe\\], whichever came first) (on-treatment analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.2","spread":"3.1"},{"groupId":"OG001","value":"-27.1","spread":"3.1"},{"groupId":"OG002","value":"-53.7","spread":"3.1"},{"groupId":"OG003","value":"-14.6","spread":"3.2"},{"groupId":"OG004","value":"-23.3","spread":"3.2"},{"groupId":"OG005","value":"-30.7","spread":"3.2"},{"groupId":"OG006","value":"-50.9","spread":"3.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"3.5"},{"groupId":"OG001","value":"-10.1","spread":"3.6"},{"groupId":"OG002","value":"-33.7","spread":"3.4"},{"groupId":"OG003","value":"-3.5","spread":"3.3"},{"groupId":"OG004","value":"-10.9","spread":"3.2"},{"groupId":"OG005","value":"-14.3","spread":"3.3"},{"groupId":"OG006","value":"-41.9","spread":"3.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (ie. up to 21 days after last injection or 3 days after the last capsule \\[whatever atorvastatin, rosuvastatin or ezetimibe\\], whichever came first).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":"3.3"},{"groupId":"OG001","value":"-12.6","spread":"3.5"},{"groupId":"OG002","value":"-37.7","spread":"3.2"},{"groupId":"OG003","value":"-4.4","spread":"3.4"},{"groupId":"OG004","value":"-12.8","spread":"3.4"},{"groupId":"OG005","value":"-16.3","spread":"3.4"},{"groupId":"OG006","value":"-42.7","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.3","spread":"3.9"},{"groupId":"OG001","value":"-15.1","spread":"4.0"},{"groupId":"OG002","value":"-36.7","spread":"3.9"},{"groupId":"OG003","value":"-6.5","spread":"3.6"},{"groupId":"OG004","value":"-17.4","spread":"3.6"},{"groupId":"OG005","value":"-21.0","spread":"3.7"},{"groupId":"OG006","value":"-47.6","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \\[whatever atorvastatin, rosuvastatin or ezetimibe\\], whichever came first).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":"3.8"},{"groupId":"OG001","value":"-18.1","spread":"4.0"},{"groupId":"OG002","value":"-40.5","spread":"3.7"},{"groupId":"OG003","value":"-7.0","spread":"3.7"},{"groupId":"OG004","value":"-18.4","spread":"3.7"},{"groupId":"OG005","value":"-23.3","spread":"3.8"},{"groupId":"OG006","value":"-50.5","spread":"3.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"2.7"},{"groupId":"OG001","value":"-11.2","spread":"2.8"},{"groupId":"OG002","value":"-27.1","spread":"2.7"},{"groupId":"OG003","value":"-4.8","spread":"2.8"},{"groupId":"OG004","value":"-11.7","spread":"2.8"},{"groupId":"OG005","value":"-15.2","spread":"2.9"},{"groupId":"OG006","value":"-33.6","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.9","spread":"2.8"},{"groupId":"OG001","value":"-13.1","spread":"2.8"},{"groupId":"OG002","value":"-38.4","spread":"2.7"},{"groupId":"OG003","value":"-9.5","spread":"2.5"},{"groupId":"OG004","value":"-14.1","spread":"2.5"},{"groupId":"OG005","value":"-20.3","spread":"2.5"},{"groupId":"OG006","value":"-36.2","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.1","spread":"3.2"},{"groupId":"OG001","value":"-17.2","spread":"3.2"},{"groupId":"OG002","value":"-40.6","spread":"3.2"},{"groupId":"OG003","value":"-13.0","spread":"2.6"},{"groupId":"OG004","value":"-19.8","spread":"2.7"},{"groupId":"OG005","value":"-27.5","spread":"2.7"},{"groupId":"OG006","value":"-42.3","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":"2.4"},{"groupId":"OG001","value":"-13.2","spread":"2.4"},{"groupId":"OG002","value":"-29.0","spread":"2.4"},{"groupId":"OG003","value":"-9.9","spread":"2.1"},{"groupId":"OG004","value":"-13.5","spread":"2.1"},{"groupId":"OG005","value":"-19.2","spread":"2.1"},{"groupId":"OG006","value":"-29.0","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis","description":"Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":null},{"groupId":"OG001","value":"68.4","spread":null},{"groupId":"OG002","value":"87.2","spread":null},{"groupId":"OG003","value":"18.5","spread":null},{"groupId":"OG004","value":"62.2","spread":null},{"groupId":"OG005","value":"65.1","spread":null},{"groupId":"OG006","value":"84.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis","description":"Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \\[whatever atorvastatin, rosuvastatin or ezetimibe\\], whichever came first (on-treatment analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.8","spread":null},{"groupId":"OG001","value":"72.2","spread":null},{"groupId":"OG002","value":"91.2","spread":null},{"groupId":"OG003","value":"18.5","spread":null},{"groupId":"OG004","value":"64.0","spread":null},{"groupId":"OG005","value":"66.2","spread":null},{"groupId":"OG006","value":"90.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis","description":"Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":null},{"groupId":"OG001","value":"50.3","spread":null},{"groupId":"OG002","value":"79.2","spread":null},{"groupId":"OG003","value":"10.2","spread":null},{"groupId":"OG004","value":"42.2","spread":null},{"groupId":"OG005","value":"54.2","spread":null},{"groupId":"OG006","value":"77.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis","description":"Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \\[whatever atorvastatin, rosuvastatin or ezetimibe\\], whichever came first (on-treatment analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"55.1","spread":null},{"groupId":"OG002","value":"82.3","spread":null},{"groupId":"OG003","value":"10.5","spread":null},{"groupId":"OG004","value":"42.4","spread":null},{"groupId":"OG005","value":"55.3","spread":null},{"groupId":"OG006","value":"83.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis","description":"Adjusted means and standard errors at Week 24 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.2","spread":"4.0"},{"groupId":"OG001","value":"-10.6","spread":"4.4"},{"groupId":"OG002","value":"-23.6","spread":"4.0"},{"groupId":"OG003","value":"-9.7","spread":"4.1"},{"groupId":"OG004","value":"-4.9","spread":"3.7"},{"groupId":"OG005","value":"0.2","spread":"3.9"},{"groupId":"OG006","value":"-30.8","spread":"4.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"2.0"},{"groupId":"OG001","value":"-0.1","spread":"2.1"},{"groupId":"OG002","value":"4.8","spread":"2.0"},{"groupId":"OG003","value":"4.7","spread":"2.7"},{"groupId":"OG004","value":"5.7","spread":"2.7"},{"groupId":"OG005","value":"2.0","spread":"2.7"},{"groupId":"OG006","value":"7.7","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis","description":"Adjusted means and standard errors at Week 24 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.7","spread":"3.7"},{"groupId":"OG001","value":"-3.3","spread":"4.1"},{"groupId":"OG002","value":"-12.0","spread":"3.7"},{"groupId":"OG003","value":"-7.3","spread":"4.1"},{"groupId":"OG004","value":"-0.5","spread":"4.0"},{"groupId":"OG005","value":"-13.9","spread":"4.1"},{"groupId":"OG006","value":"-19.1","spread":"4.10"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.5"},{"groupId":"OG001","value":"1.0","spread":"1.6"},{"groupId":"OG002","value":"7.6","spread":"1.5"},{"groupId":"OG003","value":"2.2","spread":"2.0"},{"groupId":"OG004","value":"4.7","spread":"1.9"},{"groupId":"OG005","value":"-1.8","spread":"1.9"},{"groupId":"OG006","value":"5.8","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis","description":"Adjusted means and standard errors at Week 12 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.7","spread":"4.0"},{"groupId":"OG001","value":"-5.4","spread":"4.0"},{"groupId":"OG002","value":"-24.0","spread":"4.0"},{"groupId":"OG003","value":"-1.6","spread":"4.5"},{"groupId":"OG004","value":"11.5","spread":"4.6"},{"groupId":"OG005","value":"7.9","spread":"4.5"},{"groupId":"OG006","value":"-27.9","spread":"4.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"1.8"},{"groupId":"OG001","value":"-1.7","spread":"1.8"},{"groupId":"OG002","value":"4.1","spread":"1.8"},{"groupId":"OG003","value":"3.0","spread":"2.6"},{"groupId":"OG004","value":"4.6","spread":"2.7"},{"groupId":"OG005","value":"4.6","spread":"2.7"},{"groupId":"OG006","value":"8.5","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis","description":"Adjusted means and standard errors at Week 12 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"4.2"},{"groupId":"OG001","value":"0.5","spread":"4.2"},{"groupId":"OG002","value":"-12.4","spread":"4.2"},{"groupId":"OG003","value":"-4.6","spread":"4.0"},{"groupId":"OG004","value":"-3.7","spread":"4.1"},{"groupId":"OG005","value":"-16.8","spread":"4.0"},{"groupId":"OG006","value":"-12.1","spread":"4.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.5"},{"groupId":"OG001","value":"1.7","spread":"1.4"},{"groupId":"OG002","value":"5.4","spread":"1.4"},{"groupId":"OG003","value":"1.6","spread":"1.7"},{"groupId":"OG004","value":"5.6","spread":"1.7"},{"groupId":"OG005","value":"1.6","spread":"1.7"},{"groupId":"OG006","value":"9.4","spread":"1.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":57},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Nausea","Nasopharyngitis","Back pain"]}}}